

**Van:** [CCMO - Bevoegde Instantie / Competent Authority](#)  
**Aan:** [ccmo\\_frontoffice](#)  
**Onderwerp:** FW: P1849 / NL67312.028.18: Submission Clinical Study Report Synopsis  
**Datum:** woensdag 1 september 2021 09:13:58  
**Bijlagen:** [image001.png](#)  
[image002.png](#)  
[A1. Cover Letter CA NL67312.028.18 dd 31Aug2021.pdf](#)  
[M3. Clinical Study Report Synopsis dd 19Jul2021.pdf](#)

---

Studierapport voor Marjolein.

Groet, 5.1.2.e

---

**Van:** 5.1.2.e @ppd.com>  
**Verzonden:** dinsdag 31 augustus 2021 13:41  
**Aan:** CCMO - Bevoegde Instantie / Competent Authority <bi@ccmo.nl>  
**CC:** 5.1.2.e <5.1.2.e @ppd.com>  
**Onderwerp:** P1849 / NL67312.028.18: Submission Clinical Study Report Synopsis

**Re: Submission of Clinical Study Report Synopsis**  
**Protocol number:** PVO-2A-201  
**EudraCT number:** 2017-002751-28  
**NL number:** NL67312.028.18

Dear members of the Central Committee on Research Involving Human Subjects,

On behalf of our client, Clementia Pharmaceuticals Inc. (an Ipsen company), please find enclosed the Clinical Study Report Synopsis dated 19Jul2021 for the study entitled 'A Phase 2, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Palovarotene in Subjects with Multiple Osteochondromas' registered under NL67312.028.18.

Attachments:

A1. Cover Letter NL67312.028.18 dd 31Aug2021  
M3. Clinical Study Report Synopsis dd 19Jul2021

Yours sincerely,

5.1.2.e  
5.1.2.e  
Regional Operational Delivery – The Netherlands  
Clinical Operations

**Email:** 5.1.2.e @ppd.com  
**Phone** +31 (0) 318 65 5.1.2.e  
**Mobile** +31 (0)6 5.1.2.e

This email transmission and any documents, files or previous email messages attached to it may contain information that is confidential or legally privileged. If you are not the intended recipient or a person responsible for delivering this transmission to the intended recipient, you are hereby notified that you must not read this transmission and that any disclosure, copying, printing, distribution or use of this transmission is strictly prohibited. If you have received this transmission in error, please immediately notify the sender by telephone or return email and delete the original transmission and its attachments without reading or saving in any manner.